Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: February 2025
Date Filed: February 6, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a corporate event rather than a financial statement.
Material Changes
The primary material change disclosed in this filing is the submission of Exhibit 99.1, titled "Becoming a substantial holder." This indicates a change in ownership structure where an entity or individual has acquired a significant stake in the company.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to incorporate the "Becoming a substantial holder" notice into the company's existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Review Exhibit 99.1 to identify the new substantial holder and the percentage of shares acquired.
- Verify the impact of this ownership change on the company's governance or strategic direction.
- Confirm the status of the referenced Registration Statements (Form S-8 and Form F-3) for potential future capital raises.